A5062674749- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Cancer Research and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Bladder and Urothelial Cancer Treatments
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Inflammation biomarkers and pathways
- Dermatological and COVID-19 studies
- Cancer Cells and Metastasis
- Climate Change and Health Impacts
- Hematological disorders and diagnostics
- Parvovirus B19 Infection Studies
- Energy and Environment Impacts
- Air Quality and Health Impacts
- Bone and Joint Diseases
- Chronic Lymphocytic Leukemia Research
Institute of Hematology & Blood Diseases Hospital
2020-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2020-2024
Ministry of Education of the People's Republic of China
2024
Anhui Medical University
2024
West China Medical Center of Sichuan University
2024
Triple-negative breast cancer (TNBC) is an aggressive subtype of with limited therapeutic options. IL1 receptor type 2 (IL1R2) promotes tumor-initiating cell (BTIC) self-renewal and tumor growth in TNBC, indicating that targeting it could improve patient treatment. In this study, we observed IL1R2 blockade strongly attenuated macrophage recruitment the polarization tumor-associated macrophages (TAM) to inhibit BTIC CD8+ T-cell exhaustion, which resulted reduced burden prolonged survival TNBC...
<div>Abstract<p>Triple-negative breast cancer (TNBC) is an aggressive subtype of with limited therapeutic options. IL1 receptor type 2 (IL1R2) promotes tumor–initiating cell (BTIC) self-renewal and tumor growth in TNBC, indicating that targeting it could improve patient treatment. In this study, we observed IL1R2 blockade strongly attenuated macrophage recruitment the polarization tumor-associated macrophages (TAM) to inhibit BTIC CD8<sup>+</sup> T-cell exhaustion,...
To evaluate the clinical and prognostic differences in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) children under different diagnostic criteria (World Health Organization (WHO) 2016 WHO 2022 criteria).
<p>Supplementary Figure S1</p>
<p>Table S4</p>
<p>Supplementary Figure S7</p>
<p>Supplementary Figure S10</p>
<p>Supplementary Figure S8</p>
<div>Abstract<p>Triple-negative breast cancer (TNBC) is an aggressive subtype of with limited therapeutic options. IL1 receptor type 2 (IL1R2) promotes tumor–initiating cell (BTIC) self-renewal and tumor growth in TNBC, indicating that targeting it could improve patient treatment. In this study, we observed IL1R2 blockade strongly attenuated macrophage recruitment the polarization tumor-associated macrophages (TAM) to inhibit BTIC CD8<sup>+</sup> T-cell exhaustion,...
<p>Supplementary Figure S2</p>
<p>Supplementary Figure S8</p>
<p>Supplementary Figure S11</p>
<p>Supplementary Figure S1</p>
<p>Supplementary Figure S2</p>
<p>Table S3</p>
<p>Supplementary Figure S6</p>
<p>Supplementary Figure S7</p>
<p>Table S1</p>
<p>Supplementary Figure S8</p>
<p>Table S2</p>
<p>Table S4</p>
<p>Supplementary Figure S11</p>
<p>Table S2</p>
<p>Table S1</p>
<p>Table S3</p>